The logic behind the Sunshine Act says that providing clarity on any money that pharma and device makers pay to doctors and hospitals will reduce the occurrence or appearance of corruption. . The idea is that by making those payments a matter of public record makes it undesirable for companies to try to influence medical experts.
WASHINGTON (AP) — Ending insurance discrimination against the sick was a central goal of the nation’s health care overhaul, but leading patient groups say that promise is being undermined by new barriers from insurers.
Ever since the FDA drafted a set of rules for biosimilars in 2012, a debate has been raging over whether those drugs should carry the same generic names as the products they emulate. Now, some doctors are weighing in on the issue, urging the FDA to require biosimilars to have different names than branded biotech drugs.
Amid growing regulatory action to crack down on corporate tax inversions, a top U.S. senator is urging Hospira ($HSP) to keep its operations at home and abandon plans to move abroad for taxpaying purposes.
It is August and that means that congress is on vacation. Vacation from doing what? I don’t know. (note I do believe that our elected officials are hard working) But when they return after Labor Day, there are a number of issues that they are going to have to deal with before taking a…
On July 16th I wrote a piece about hi-copay specialty tiers, and how insurance companies are using them to restrict access to specialty pharma. In the hi-copay specialty tier, instead of pay a flat fee for the medications, patients must instead pay for a percentage of the drug cost, anywhere from 20%-50%.